Radioactive drug for previously treated gut or adrenal tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer called gastrointestinal neuroendocrine tumor (GI NET) or pheochromocytoma/paraganglioma (PPGL) that has spread or cannot be removed by surgery.
- You have already had at least one treatment with a targeted radiation therapy that goes through your bloodstream.
- A recent PET scan shows that more than half of your tumor has a specific receptor (SSTR) that the study drug targets.
- Your disease has been getting worse (growing or more symptoms) in the last 3 years.
- You are 18 years or older, and your overall health is good enough to be up and about (ECOG score 0 or 1).
- Your kidney, liver, and blood cell counts are within safe levels as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug, [212Pb]VMT-Alpha-NET, that targets a protein on certain cancer cells. It is for people with specific types of advanced cancers that have gotten worse and are not responding to standard treatments.
This trial tests a targeted form of radiation made to stick to specific “somatostatin receptor” markers on tumors. It is designed for people with advanced, receptor-positive neuroendocrine tumors or meningioma who may have had prior treatments and need more options.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
Hear when a new Somatostatin Receptor Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.